This research study is currently not recruiting patients.

A phase II study of nivolumab cabiralizumab and stereotactic body radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer

Brief description of study

If you have been diagnosed with pancreatic cancer, you may qualify for this Phase II study. The main goal of this study is to determine if cabiralizumab and nivolumab, as well as radiotherapy (radiation therapy) is safe and tolerable while treating your cancer, as well as to determine the effects the study drugs and therapy will have on your cancer treatment.

Clinical Study Identifier: s17-01430 Identifier: NCT03599362